Xuedong Sun
Shanghai, 200030, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
A bi-specific CAR-T cell therapy targeting CD19 and CD22 in relapsed or refractory B-ALL.
Journal: Clinical and experimental medicine
Published: January 05, 2025
A 5-Year Follow-up Clinical Study of the B-cell Maturation Antigen Chimeric Antigen Receptor T-cell Therapy HDS269B in Patients with Relapsed or Refractory Multiple Myeloma.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: February 04, 2024
Correction: CD19/CD22 bispecific CAR-T cells for MRD-positive adult B cell acute lymphoblastic leukemia: a phase I clinical study.
Journal: Blood cancer journal
Published: April 13, 2023
Subsequent anti-myeloma therapy after maturation antigen (BCMA) chimeric antigen receptor (CAR)-T cell (HDS269B) treatment in patients with relapsed/refractory multiple myeloma.
Journal: American journal of hematology
Published: July 03, 2022
CAR-T cell therapy targeting B cell maturation antigen is effective for relapsed/refractory multiple myeloma, including cases with poor performance status.
Journal: American journal of hematology
Published: December 26, 2021
Preparation of cysteine-click maltose modified silica as a hydrophilic interaction liquid chromatography material for the enrichment of glycopeptides
Journal: Se pu = Chinese journal of chromatography
Published: October 20, 2017
Showing 1-9 of 9
Last Updated: 09/26/2026